Relationship between genetic ploymorphisms and platin-based chemotherapy efficacy

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-TNC-10000895

Enrollment

Unknown

Registered

2009-12-03

Start date

2006-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

cancer patients without certain genotype:platium-based chemotherapy

cancer patients with certain genotype:platium-based chemotherapy

Eligibility

Sex/Gender

All

Age

50 Years to 70 Years

Inclusion criteria

Inclusion criteria: Diagnosis as lung cancer patient and accepted platin-based chemotherapy

Exclusion criteria

Exclusion criteria: Accepted other therapies

Design outcomes

Primary

Measure	Time frame
toxicity and side-effect of platium;Response Evaluation Criteria in Solid Tumor;	—

Secondary

Measure	Time frame
suvivial time;	—

Countries

China

Contacts

Public ContactLiu Zhaoqian

liuzhaoqian63@126.com+86 0731 84805380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026